CRISPR Therapeutics
CRSP
CRSP
170 hedge funds and large institutions have $929M invested in CRISPR Therapeutics in 2019 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
10% more funds holding
Funds holding: 155 → 170 (+15)
7.11% more ownership
Funds ownership: 42.63% → 49.75% (+7.1%)
35% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $21.6M
Holders
170
Holding in Top 10
6
Calls
$14.1M
Puts
$21.6M
Top Buyers
| 1 | +$59.6M | |
| 2 | +$28.9M | |
| 3 | +$28.6M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$24.9M |
| 5 |
VVM
Versant Venture Management
San Francisco,
California
|
+$22.9M |
Top Sellers
| 1 | -$18.8M | |
| 2 | -$15.5M | |
| 3 | -$12.7M | |
| 4 |
Two Sigma Advisers
New York
|
-$8.35M |
| 5 |
AC
Armistice Capital
New York
|
-$3.29M |